MAPT and Alzheimer disease: Given the clinical implications of AD co-pathology and possible impact on treatment outcomes, the inclusion of amyloid-β and tau biomarkers in LBD clinical trials have the potential to stratify accordingly and select subgroups most likely to benefit as well as confirming target engagement in DMTs.